Provider file · open file
Ivim Health: the file as of August 17, 2026
Ivim Health appears in current independent comparison coverage of the compounded-semaglutide field — enough to earn a directory row, not enough to earn numbers: pricing, plan structure, pharmacy identity, and terms are all uncaptured as of this writing. This page exists so the directory’s completeness claim stays honest: presence acknowledged, everything else open.
What closes the file
A direct capture of published pricing (on-record), then the standard anatomy: all-in monthly, dose behavior, the four fee families, pharmacy name and class, exit terms. Until then, Ivim appears in the index as an open row and nowhere in any ranking.
Standing rules apply: compounded products are not FDA-approved; trial certificates belong to the brands; tier upgrades require the same audit the anchor passed, and corrections@ outranks this page with dated evidence. Field context: the cost index · tirzepatide value board · semaglutide value board.
No outbound link — open file.